Selpercatinib is a selective RET kinase inhibitor approved for the treatment of cancers characterized by RET gene alterations, such as specific types of non-small cell lung cancer and thyroid cancers.… Read more

Selpercatinib is a selective RET kinase inhibitor approved for the treatment of cancers characterized by RET gene alterations, such as specific types of non-small cell lung cancer and thyroid cancers. To support the rigorous quality control and safety monitoring required for this oncology medication, this category provides a comprehensive selection of high-quality reference standards. These include the active pharmaceutical ingredient, relevant degradation products like N-oxide, amide, and aldehyde impurities, and synthetic intermediates essential for accurate impurity profiling during development and manufacturing. Additionally, the availability of stable isotope labelled compounds provides laboratories with critical tools for precise quantification and validation of complex analytical methods, including liquid chromatography-mass spectrometry workflows. By utilizing these characterized reference materials, researchers and quality control scientists can effectively maintain the purity assessment and compliance standards necessary for the development and testing of this targeted therapy.